Blumberg Richard P. 4

4 · GUIDED THERAPEUTICS INC · Filed May 5, 2026

Research Summary

AI-generated summary of this filing

Updated May 5, 2026

Guided Therapeutics (GTHP) 10% Owner Richard Blumberg Exercises Warrants

What Happened

Richard P. Blumberg, a reported 10% owner of Guided Therapeutics, exercised 1,000,000 warrants at $0.20 per share by paying $200,000 (reported Feb 25, 2026). He also converted preferred stock into common stock and received several share issuances tied to accrued dividends and an equity award.
Conversions on March 26, 2026 converted 260 shares of Series F preferred into 1,040,000 common shares and 88 shares of Series F-2 preferred into 352,000 common shares (conversion price $0.25). Additional share issuances of 56,093 and 19,038 common shares were issued as payment of accrued dividends (conversion price $0.2773). An equity award vested such that 110,000 shares were acquired (one-fourth vested March 10, 2026; remainder vests through 2029).
Separately, 900,000 warrants with a $0.30 exercise price expired unexercised on March 1, 2026, and one set of 1,000,000 warrants with a $0.65 exercise price had its expiration extended to Sept 1, 2027 as part of an exchange agreement.

Key Details

Primary dates and amounts:
- Feb 25, 2026: Exchanged warrants and exercised 1,000,000 warrants at $0.20 each; cash paid = $200,000 (F1).
- Mar 1, 2026: 900,000 warrants at $0.30 expired unexercised (F2).
- Mar 10, 2026: 110,000 shares vested from an award (one‑quarter vested; remainder vests monthly to Mar 10, 2029) (F3).
- Mar 26, 2026: Converted 260 Series F into 1,040,000 common and 88 Series F‑2 into 352,000 common; also received 56,093 and 19,038 shares for accrued dividends (F4–F7).
Total common shares received from these conversions (reported in filing): 1,392,000 (from Series F and F‑2 conversions) plus 1,000,000 from the exercised warrants and other smaller issuances/awards.
Shares owned after the transactions: not specified in the filing.
Notable footnotes: exchange agreement swapped warrants to lower strikes (and triggered immediate exercise), extension of some warrants' expiration to Sept 1, 2027, and dividend conversions at $0.2773; conversions used a $0.25 conversion price for stated-value preferred (see F1–F7).
Filing date: May 5, 2026 (the report covers transactions from Feb–Mar 2026). The filing does not indicate a late-filing designation.

Context

These were primarily derivative exercises and conversions (not open-market buys/sells). Blumberg paid cash ($200K) to exercise warrants rather than a cashless exercise.
Conversions of preferred into large blocks of common stock increase his common shares outstanding and can be dilutive to other holders; such conversions are common when preferred shares convert at set rates/prices.
As a reported 10% owner (not an unaffiliated retail executive), these moves reflect changes to his ownership structure via derivative exercises and preferred conversions rather than routine small purchases or sales.

Insider Transaction Report

Form 4

Period: 2026-02-25

GUIDED THERAPEUTICS INCGTHP

Blumberg Richard P.

Director10% Owner

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-25+1,000,000→ 8,924,180 total
Other
Common Stock
[F4]
2026-03-26+56,093→ 8,980,273 total
Other
Preferred Series F Stock
[F5]
2026-03-26−260→ 0 total
Other
Common Stock
[F5]
2026-03-26+1,040,000→ 10,020,273 total
Other
Common Stock
[F6]
2026-03-26+19,038→ 10,039,311 total
Other
Preferred Series F-2 Stock
[F7]
2026-03-26−88→ 0 total
Other
Common Stock
[F7]
2026-03-26+352,000→ 10,391,311 total
Disposition to Issuer
Warrants
[F1]
2026-02-25−1,000,000→ 0 total
Exercise: $0.65From: 2022-09-01Exp: 2026-09-01→ Common Stock (1,000,000 underlying)
Award
Warrants
[F1]
2026-02-25+1,000,000→ 1,000,000 total
Exercise: $0.65From: 2026-02-25Exp: 2027-09-01→ Common Stock (1,000,000 underlying)
Disposition to Issuer
Warrants
[F1]
2026-02-25−1,000,000→ 0 total
Exercise: $0.50From: 2022-09-01Exp: 2026-09-01→ Common Stock (1,000,000 underlying)
Award
Warrants
[F1]
2026-02-25+1,000,000→ 1,000,000 total
Exercise: $0.20From: 2026-02-25Exp: 2026-02-25→ Common Stock (1,000,000 underlying)
Exercise/Conversion
Warrants
[F1]
2026-02-25$0.20/sh−1,000,000$200,000→ 0 total
Exercise: $0.20From: 2026-02-25Exp: 2026-02-25→ Common Stock (1,000,000 underlying)
Expiration (Short)
Warrants
[F2]
2026-03-01$0.30/sh−900,000$270,000→ 2,700,000 total
Exercise: $0.30From: 2023-03-01Exp: 2026-03-01→ Common Stock (900,000 underlying)
Award
Stock Options
[F3]
2026-03-10+110,000→ 110,000 total
Exercise: $0.29Exp: 2036-03-09→ Common Stock (110,000 underlying)

Footnotes (7)

[F1]During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027.
[F2]900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised.
[F3]One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.
[F4]These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.
[F5]On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.
[F6]These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773.
[F7]On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price.

Signature

/s/ Richard P. Blumberg|2026-05-05

Documents

1 file

4
form4.xmlPrimary
FORM 4